Meet
Novo Nordisk lagged behind its archive Eli Lilly, an obesity in the drug market. Composite GLP-1 drugs have become such a problem that Novo Nordisk has changed its CEO. Expectations are so low that the upcoming Wegovy tablet can send Novo Nordisk next year. 10 shares we like more than Novo Nordisk › Denmark’s pharmaceutical … Read more